ProgressImage ProgressImage
Aurobindo Pharma Ltd
Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code 524804 border-img ISIN Demat INE406A01037 border-img Book Value 369.16 border-img NSE Symbol AUROPHARMA border-img Div & Yield % 0 border-img Market Cap ( Cr.) 86156.11 border-img P/E 40.19 border-img EPS 36.91 border-img Face Value 1
ParticularsMar 2025
()
Mar 2024
()
Mar 2023
()
Mar 2022
()
Mar 2021
()
Mar 2020
()
INCOME :       
Sales Turnover 10933.3010645.648457.0011287.1415823.6813370.77
Excise Duty 0.000.000.000.000.000.00
Net Sales 10933.3010645.648457.0011287.1415823.6813370.77
Other Income 328.12670.10443.92670.99589.86388.79
Stock Adjustments 67.66116.23263.95-45.51-2.99238.67
Total Income 11329.0811431.979164.8711912.6216410.5513998.23
EXPENDITURE :       
Raw Materials 5675.345964.484755.955800.747241.836819.85
Power & Fuel Cost 185.59191.58167.86477.99512.34526.31
Employee Cost 1063.07980.56890.531600.041735.421577.14
Other Manufacturing Expenses 426.63414.51328.42705.68925.86814.44
Selling & Administrative Expenses 960.27822.21939.381009.361069.84938.36
Miscellaneous Expenses 132.49164.49148.96249.13215.57235.47
Less : Pre-operative Expenses Capitalised 0.000.000.000.000.000.00
Total Expenditure 8443.398537.837231.109842.9411700.8610911.57
Operating Profit 2885.692894.141933.772069.684709.693086.66
Interest 230.04182.6074.5816.9428.68243.28
Gross Profit 2655.652711.541859.192052.744681.012843.38
Depreciation 297.20254.58243.26415.26488.00473.33
Profit Before Tax 2358.452456.961615.931637.484193.012370.05
Tax 627.37598.08412.16379.701043.34492.28
Fringe Benefit tax 0.000.000.000.000.000.00
Deferred Tax -15.71-95.26-23.34-196.9336.760.89
Reported Net Profit 1746.791954.141227.111454.713112.911876.88
Extraordinary Items 5.483.289.94-81.27-0.13-1.90
Adjusted Net Profit 1741.311950.861217.171535.983113.041878.78
Adjustment below Net Profit -5.26-1.698.281.69-6.42-44.88
P & L Balance brought forward 18348.8716660.0815864.1414671.4111799.3010143.08
Statutory Appropriations 0.000.000.000.000.000.00
Appropriations 0.00263.66439.45263.67234.38175.78
P & L Balance carried down 20090.4018348.8716660.0815864.1414671.4111799.30
Dividend 0.00263.66439.450.000.000.00
Preference Dividend 0.000.000.000.000.000.00
Equity Dividend % 0.00450.00750.00900.00400.00300.00
Dividend Per Share(Rs) 0.004.507.509.004.003.00
Earnings Per Share-Unit Curr 30.0833.3520.9424.8353.1332.03
Earnings Per Share(Adj)-Unit Curr 30.0833.3520.9424.8353.1332.03
Book Value-Unit Curr 353.55336.62307.80292.15271.80222.78
Book Value(Adj)-Unit Curr 353.55336.62307.80292.15271.80222.78
`

ATTENTION INVESTORS : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day ...Issued in the interest of investors.   Prevent Unauthorized Transactions in your demat account Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day...... issued in the interest of investors.    KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.      No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment.No worries for refund as the money remains in investor's account.

Investor Protection and Arbitration Exchange Circulars and Rules - NSE BSE

Filing of complaints on SCORES – Easy & quick   |    Advisory for Investors   |    AP Details - NSE   |    AP Details - BSE   |    AP Details - MCX
KYC Process Flow   |    Investor Grievance Redressal Process Flow   |   Online Grievance Redressal   |    Voluntary Freezing/Blocking of Trading Account   |    Website Accessibility Statement

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing.

We are integrated with TradingView, a leading charting platform providing advanced financial visualization tools, technical indicators, and market analysis capabilities for traders and investors worldwide.

x
x
×
Let's Chat
imsl-img
close
refresh